Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

Bevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer. The present study was to determine the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2/neu)-negative MBC.Bevacizumab,...

Full description

Bibliographic Details
Main Authors: Ting Li, Biyun Wang, Zhonghua Wang, Joseph Ragaz, Jian Zhang, Si Sun, Jun Cao, Fangfang Lv, Leiping Wang, Sheng Zhang, Chen Ni, Zhenhua Wu, Jie Xie, Xichun Hu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4506015?pdf=render

Internet

http://europepmc.org/articles/PMC4506015?pdf=render

Similar Items